Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.